{"id":"W2137323340","doi":"10.1186/1477-7525-11-82","title":"Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study","year":2013,"lang":"en","type":"article","venue":"Health and Quality of Life Outcomes","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Celgene","keywords":"Apremilast; Medicine; Placebo; Minimal clinically important difference; Dermatology Life Quality Index; Psoriasis; Quality of life (healthcare); Visual analogue scale; Randomized controlled trial; Internal medicine; Physical therapy; Dermatology; Alternative medicine; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001654667,0.000389596,0.003074165,0.0001884617,0.0001081828,0.00002084421,0.0001253196,0.0001188631,0.00002233486],"category_scores_gemma":[0.0004467502,0.0001998648,0.0001930009,0.0001543126,0.0001023459,0.000139066,0.00002619408,0.00009425248,0.000003734733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006337473,"about_ca_system_score_gemma":0.0002205558,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04750917,"about_ca_topic_score_gemma":0.008194921,"domain_scores_codex":[0.9938778,0.0027705,0.002312702,0.0004811861,0.0001535053,0.0004043355],"domain_scores_gemma":[0.9965153,0.001755869,0.0009897434,0.0005109371,0.00009967211,0.0001285334],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4000823,0.01000646,0.523305,0.00003689094,0.001405507,0.000005973495,0.04946155,0.00001065119,0.0001296145,0.00001128621,0.00003655827,0.0155082],"study_design_scores_gemma":[0.7378526,0.005231773,0.2407105,0.00004997267,0.0001755319,9.759463e-7,0.01539898,0.000008488132,0.0002986542,0.00003922944,0.00002407365,0.0002092992],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902768,0.001150923,0.000005607133,0.0009544993,0.0002096114,0.006999294,0.0003676781,0.00001806061,0.00001748389],"genre_scores_gemma":[0.9971904,0.0001565678,0.0001702611,0.00109074,0.000009575871,0.001054493,0.0002228896,0.0000132019,0.00009189871],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3377702,"threshold_uncertainty_score":0.9588335,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05339083400482784,"score_gpt":0.3399360892887135,"score_spread":0.2865452552838857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}